AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18766474 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician group (PG)
Number of subjects: 264
Study 18766474 — intervention group
Group type: COMPARATOR
Intervention: Nurse group (NG)
Number of subjects: 264
Study 17325297 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program on systems-based practice competencies
Number of subjects: 693
Study 17325297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 693
Study 15346110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 50
Study 15346110 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 50
Study 11588903 — intervention group
Group type: COMPARATOR
Intervention: 0 g of ground flaxseed
Number of subjects: 28
Study 11588903 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of ground flaxseed
Number of subjects: 28
Study 11588903 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of ground flaxseed
Number of subjects: 28
Study 9519318 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg daily
Number of subjects: 18
Study 9519318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8080597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 0
Study 8080597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2762082 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual components of a televised program
Number of subjects: 80
Study 2762082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of visual and auditory input
Number of subjects: 80
Study 2762082 — intervention group
Group type: COMPARATOR
Intervention: Auditory components of a televised program
Number of subjects: 80
Study 406102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 20
Study 406102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31400049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic valgancyclovir
Number of subjects: 0
Study 31400049 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive valgancyclovir
Number of subjects: 0
Study 31400049 — intervention group
Group type: COMPARATOR
Intervention: High-dose valacyclovir
Number of subjects: 0
Study 29202456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (neuroleptic)
Number of subjects: 0
Study 25601966 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 800 mg/m² twice daily throughout the 21-day cycle (Ccont)
Number of subjects: 195
Study 25601966 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1,250 mg/m² twice daily for 2 weeks on and 1 week off (Cint)
Number of subjects: 195
Study 24009092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT)
Number of subjects: 0
Study 24009092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) with PSFR cutoffs
Number of subjects: 0
Study 21269278 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 17
Study 19922995 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg daily
Number of subjects: 3846
Study 19922995 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg daily
Number of subjects: 3846
Study 16630454 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP (0.15 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(‐1).min(‐1) for 24 hours, n = 105)
Number of subjects: 209
Study 16630454 — intervention group
Group type: COMPARATOR
Intervention: NIT (starting at 10 microg/min and increasing 5 microg/min each time till clinical effective dose for 24 hours, n = 104)
Number of subjects: 209
Study 16630454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rhBNP and NIT
Number of subjects: 209
Study 14652125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group A)
Number of subjects: 105
Study 14652125 — intervention group
Group type: COMPARATOR
Intervention: No epidural anesthesia (Group B)
Number of subjects: 105
Study 10778764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 103
Study 10778764 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 103
Study 9051872 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosulide (20 mg twice a day)
Number of subjects: 19
Study 9051872 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 19
Study 8404438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 19% of energy from sucrose
Number of subjects: 12
Study 8404438 — intervention group
Group type: COMPARATOR
Intervention: Diet with < 3% of energy from sucrose (starch diet)
Number of subjects: 12
Study 8404438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study 3538843 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g protein
Number of subjects: 8
Study 3538843 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 8
Study 3538843 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g protein + 50 g glucose
Number of subjects: 8
Study 3538843 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting baseline)
Number of subjects: 8
Study 31925833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: accelerometer paired with financial incentives and health engagement questions
Number of subjects: 127
Study 31925833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study 31925833 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer
Number of subjects: 127
Study 29718297 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer (FET)
Number of subjects: 3665
Study 29718297 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 3665
Study 26957232 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH) applied on day 3 frozen embryos before frozen embryo transfer (FET)
Number of subjects: 413
Study 26957232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment applied on frozen embryo before transfer)
Number of subjects: 413
Study 26957232 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH)
Number of subjects: 413
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for SAD, 16 weekly sessions of individual CBT.
Number of subjects: 0
Study 24632110 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 0
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 0
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 0
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal success increases
Number of subjects: 0
Study 24632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal success increases pre‐to‐post‐CBT
Number of subjects: 0
Study 22716131 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary counseling and testing, community mobilization and post-test support services intervention
Number of subjects: 0
Study 19781591 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP treatment (Tooth Mousse, GC Corp.) for 60 min x 7 days with 2-step self-etching primer adhesive (Clearfil SE Bond, Kuraray Medical)
Number of subjects: 34
Study 19781591 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP treatment (Tooth Mousse, GC Corp.) for 60 min x 7 days with 'all-in-one' adhesive (G-Bond, GC Corp.)
Number of subjects: 34
Study 19781591 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated dentine) with 2-step self-etching primer adhesive (Clearfil SE Bond, Kuraray Medical)
Number of subjects: 34
Study 19781591 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated dentine) with 'all-in-one' adhesive (G-Bond, GC Corp.)
Number of subjects: 34
Study 18441323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily (S80)
Number of subjects: 39
Study 18441323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10)
Number of subjects: 39
Study 11925401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% icodextrin
Number of subjects: 62
Study 11925401 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactated saline (RLS)
Number of subjects: 62
Study 10089069 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (THP‐COP) containing pirarubicin (30 mg/m2; day 1)
Number of subjects: 37
Study 10089069 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (modified CHOP) containing doxorubicin (30 mg/m2; day 1)
Number of subjects: 37
Study 10089069 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (THP‐COPE) including etoposide (80 mg/m2; day 1) in addition to regimen A
Number of subjects: 37
Study 7744384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen oral drop (1000 mg)
Number of subjects: 8
Study 7744384 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen tablet (1000 mg)
Number of subjects: 8
Study 2721259 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline, 15 mg daily for five weeks
Number of subjects: 17
Study 2721259 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 30380038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with sulfadoxine‐pyrimethamine plus artesunate
Number of subjects: 0
Study 30380038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28734154 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational smoking cessation intervention emphasizing reduced drinking
Number of subjects: 317
Study 28734154 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation intervention (brief informational)
Number of subjects: 317
Study 28734154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (motivational and informational)
Number of subjects: 317
Study 24949564 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR; 1 mg twice daily)
Number of subjects: 40
Study 24949564 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX; 25 mg once daily)
Number of subjects: 40
Study 24949564 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus Naltrexone (VAR + NTX)
Number of subjects: 40
Study 24949564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) - three manualized sessions including one physical activity exposure session
Number of subjects: 40
Study 23507293 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioner
Number of subjects: 40
Study 23507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study 22007505 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 109
Study 22007505 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge guidance
Number of subjects: 109
Study 19351942 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise training (n = 1172)
Number of subjects: 2331
Study 19351942 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 1159)
Number of subjects: 2331
Study 16428996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsterile tape
Number of subjects: 3
Study 16428996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub-Guard
Number of subjects: 3
Study 16428996 — intervention group
Group type: EXPERIMENTAL
Intervention: StatLock
Number of subjects: 3
Study 15596721 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Number of subjects: 0
Study 15596721 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 0
Study 11387299 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg gestodene
Number of subjects: 23
Study 11387299 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg gestodene
Number of subjects: 23
Study 11387299 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 9004057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg or 600 mg
Number of subjects: 30
Study 7680833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion (2 micrograms.kg‐1.min‐1)
Number of subjects: 6
Study 7680833 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 3100145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN)
Number of subjects: 45
Study 3100145 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (NTG)
Number of subjects: 45
Study 30732125 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/d) + chemotherapy
Number of subjects: 175
Study 30732125 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 175
Study 30732125 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib + chemotherapy
Number of subjects: 175
Study 28532861 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Communication (OpenComm)
Number of subjects: 200
Study 28532861 — intervention group
Group type: EXPERIMENTAL
Intervention: AskShareKnow
Number of subjects: 200
Study 28532861 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 200
Study 25156125 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival glycine powder air polishing (GPAP)
Number of subjects: 25
Study 25156125 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling with hand instruments (SRP)
Number of subjects: 25
Study 25156125 — intervention group
Group type: COMPARATOR
Intervention: Subgingival ultrasonic debridement (UD)
Number of subjects: 25
Study 25156125 — intervention group
Group type: COMPARATOR
Intervention: No subgingival treatment (NT)
Number of subjects: 25
Study 23558080 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkAide (WA) foot-drop stimulator
Number of subjects: 93
Study 23558080 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ankle-foot orthosis (AFO)
Number of subjects: 93
Study 23558080 — intervention group
Group type: COMPARATOR
Intervention: AFO
Number of subjects: 93
Study 23558080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WA and AFO
Number of subjects: 93
Study 23558080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 93
Study 23558080 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkAide (WA)
Number of subjects: 93
Study 22420439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal reflux
Number of subjects: 20
Study 22420439 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal reflux
Number of subjects: 20
Study 22420439 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nasopharyngeal reflux incidence
Number of subjects: 20
Study 19346194 — intervention group
Group type: EXPERIMENTAL
Intervention: HT treatment group (2 mg 17beta‐estradiol + 1 mg norethisterone acetate)
Number of subjects: 40
Study 19346194 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study 16940448 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg thrice daily)
Number of subjects: 23
Study 16940448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone (TSH) testing
Number of subjects: 883
Study 11727184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo- and chemoimmunotherapy
Number of subjects: 3696
Study 11727184 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 3696
Study 18476190 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin (400 mg, single oral dose)
Number of subjects: 380
Study 18476190 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (400 mg, single oral dose)
Number of subjects: 380
Study 8502095 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery excision
Number of subjects: 28
Study 8502095 — intervention group
Group type: COMPARATOR
Intervention: Dissection/snare followed by point coagulation
Number of subjects: 28
Study 3581488 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior rhinomanometry
Number of subjects: 15
Study 3581488 — intervention group
Group type: COMPARATOR
Intervention: Anterior rhinomanometry
Number of subjects: 15
Study 3581488 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nasal resistance derived from posterior rhinomanometry
Number of subjects: 15
Study 27473218 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal OGTT response
Number of subjects: 35
Study 27473218 — intervention group
Group type: COMPARATOR
Intervention: Abnormal OGTT response
Number of subjects: 35
Study 27473218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetic patients
Number of subjects: 35
Study 27634669 — intervention group
Group type: EXPERIMENTAL
Intervention: CASA intervention (nurse-led symptom management and social worker support)
Number of subjects: 0
Study 27634669 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24621826 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Zusanli (ST36) and Sanyinjiao (SP6)
Number of subjects: 80
Study 24621826 — intervention group
Group type: COMPARATOR
Intervention: Etomidate anesthesia
Number of subjects: 80
Study 24621826 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (non-acupoints)
Number of subjects: 80
Study 24621826 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 80
Study 21840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-enhanced voice therapy using portable digital media players with clinician and self-videos
Number of subjects: 13
Study 21840169 — intervention group
Group type: COMPARATOR
Intervention: Standard of care voice therapy with written homework descriptions
Number of subjects: 13
Study 20685923 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored cue associated with an executed movement
Number of subjects: 0
Study 20685923 — intervention group
Group type: COMPARATOR
Intervention: Colored cue associated with an observed movement
Number of subjects: 0
Study 17846098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient odor during task performance
Number of subjects: 0
Study 17846098 — intervention group
Group type: COMPARATOR
Intervention: Relevant control groups
Number of subjects: 0
Study 16455288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Balance gel delivered by slow release via a novel intra‐oral device
Number of subjects: 22
Study 16455288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Balance gel in bolus form
Number of subjects: 22
Study 16455288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Balance gel (both forms)
Number of subjects: 22
Study 14581273 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-PAI
Number of subjects: 108
Study 14581273 — intervention group
Group type: COMPARATOR
Intervention: PAI
Number of subjects: 108
Study 10971552 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (short-term)
Number of subjects: 17
Study 10971552 — intervention group
Group type: COMPARATOR
Intervention: Baseline ventilation
Number of subjects: 17
Study 10971552 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO during hyperventilation
Number of subjects: 17
Study 10971552 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal perfusion abnormalities
Number of subjects: 17
Study 8855797 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide, testolactone, reduced hydrocortisone dose (from 12.9 to 7.9 mg/m2 day), and fludrocortisone
Number of subjects: 12
Study 8855797 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone and fludrocortisone treatment
Number of subjects: 12
Study 1613128 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (120 mg every 8 hr)
Number of subjects: 12
Study 1613128 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (90 mg every 8 hr)
Number of subjects: 12
Study 1613128 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (200 mg every 12 hr)
Number of subjects: 12
Study 1613128 — intervention group
Group type: COMPARATOR
Intervention: placebo (every 12 hr)
Number of subjects: 12
Study 6512783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 40
Study 6512783 — intervention group
Group type: COMPARATOR
Intervention: Other delivery routes (not specified)
Number of subjects: 40
Study 31246522 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine and cytarabine (Clo+AraC, n = 129)
Number of subjects: 285
Study 31246522 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine, daunorubicin, and etoposide (HD-ADE, n = 133)
Number of subjects: 285
Study 31246522 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine and cytarabine (Clo+AraC)
Number of subjects: 285
Study 31246522 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine, daunorubicin, and etoposide (HD-ADE)
Number of subjects: 285
Study 29693366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision screening accompanied by eye exams and free eyeglasses
Number of subjects: 0
Study 29693366 — intervention group
Group type: COMPARATOR
Intervention: Enhanced vision screening alone
Number of subjects: 0
Study 26703245 — intervention group
Group type: EXPERIMENTAL
Intervention: Final PCWP ≥ 20 mmHg
Number of subjects: 151
Study 26703245 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher final right atrial pressure
Number of subjects: 151
Study 26703245 — intervention group
Group type: EXPERIMENTAL
Intervention: Final CI
Number of subjects: 151
Study 25010538 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL gait training
Number of subjects: 22
Study 25010538 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 22
Study 23514679 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 180
Study 23514679 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch (37% phosphoric acid etchant)
Number of subjects: 180